Target intelligence / Profile preview

Kinesin family member 5A (KIF5A)

Target
KIF5A
Molecular classification
Motor protein, Enzyme, Cytoskeletal protein
01

Overview

Kinesin family member 5A (KIF5A) is a motor protein belonging to the kinesin superfamily, characterized by its role in ATP-dependent intracellular transport along microtubules, primarily within neurons. KIF5A is crucial for anterograde (forward) transport of organelles, proteins, and RNAs in axons and dendrites, supporting neuronal survival and function. Structurally, it contains an N-terminal motor domain responsible for microtubule binding and movement, a central coiled-coil stalk for dimerization, and a C-terminal domain for cargo binding. Mutations in the KIF5A gene are linked to hereditary spastic paraplegia 10, amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth disease, reflecting its importance in neuronal health and axonal transport. KIF5A dysfunction can lead to the accumulation of mislocalized proteins and organelles, contributing to neurodegeneration. Emerging small molecule inhibitors, such as epigallocatechin gallate, have been computationally explored for disease intervention by disrupting aberrant mutated KIF5A activity.

Other names
KIF5ASPG10 (previous HGNC symbol)Kinesin heavy chain isoform 5AKinesin superfamily protein 5A
02

Mechanism of action

Inhibition of microtubule motor activity

03

Biological functions

Microtubule-based intracellular transportAnterograde axonal transportTransport of organelles, proteins, and RNA in neuronsRegulation of neuronal cell survival and deathMitochondrial transport in axonsRegulation of cell signaling microdomains (via transport of vesicles and proteins)
04

Disease associations

Neurodegenerative disease (Amyotrophic lateral sclerosis, ALS)Hereditary spastic paraplegia (SPG10)Charcot-Marie-Tooth disease type 2Alzheimer’s disease (implicated in mitochondrial axonal transport modulated by amyloid-β)
05

Safety considerations

Disruption of KIF5A function could impair essential axonal transport, potentially causing neuronal dysfunction and degeneration
06

Interacting drugs

Epigallocatechin gallate (EGCG, investigated as a KIF5A binding inhibitor in ALS models)
07

Biomarkers

KIF5A mutations (notably S291F and other pathogenic nsSNPs) as biomarkers for ALS, hereditary spastic paraplegia, and Charcot-Marie-Tooth disease type 2

Beyond the preview

Go deeper on Kinesin family member 5A (KIF5A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinesin family member 5A (KIF5A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call